Bioorganic and Medicinal Chemistry Letters p. 4080 - 4083 (2012)
Update date:2022-08-03
Topics:
Subasinghe, Nalin L.
Wall, Mark J.
Winters, Michael P.
Qin, Ning
Lubin, Mary Lou
Finley, Michael F.A.
Brandt, Michael R.
Neeper, Michael P.
Schneider, Craig R.
Colburn, Raymond W.
Flores, Christopher M.
Sui, Zhihua
Selective blockers of the N-type calcium channel have proven to be effective in animal models of chronic pain. However, even though intrathecally delivered synthetic ω-conotoxin MVIIA from Conus magnus (ziconotide [Prialt]) has been approved for the treatment of chronic pain in humans, its mode of delivery and narrow therapeutic window have limited its usefulness. Therefore, the identification of orally active, small-molecule N-type calcium channel blockers would represent a significant advancement in the treatment of chronic pain. A novel series of pyrazole-based N-type calcium channel blockers was identified by structural modification of a high-throughput screening hit and further optimized to improve potency and metabolic stability. In vivo efficacy in rat models of inflammatory and neuropathic pain was demonstrated by a representative compound from this series.
Contact:+86-731-84427351
Address:154 JIANXIANG SOUTH ROAD
Anhui Asahikasei Chemical Co., Ltd
Contact:86-551-4259770
Address:No. 88 Linquan Road Hefei Anhui China
Jiande City Silibase Silicone New Material Manufacture Co., Ltd.
Contact:15967177856
Address:Genglou Industrial Development Area
WENZHOU M&C FOREIGN TRADE CO.,LTD.
Contact:+86-577-88862917
Address:No.8 Liming West Road,Wenzhou,zhejiang,China
Contact:13357117572
Address:No.149 Shiji dadao Road.
Doi:10.1039/c0cc04348f
(2011)Doi:10.1016/j.bmcl.2015.07.023
(2015)Doi:10.1016/0040-4039(91)85090-R
(1991)Doi:10.1021/ja00167a070
(1990)Doi:10.1016/j.bmcl.2010.11.010
(2011)Doi:10.1021/ja111540g
(2011)
